On June 23, MicroPort MedBot-B rose 5.37% in regular trading, trading at HK$23.96/share, with turnover of HK$45.31 million, reversing the prior week's consecutive declines driven by competitive pressure concerns.

On the news front, the company announced that its self-developed Toumai laparoscopic surgical robot for remote surgery across all clinical departments has officially obtained EU CE certification, covering urology, general surgery, thoracic surgery, and gynecology. This makes Toumai the world's first remote surgical robot to receive the EU CE mark, adding market access to over 30 European countries and bringing total regulatory approvals to nearly 20 countries and regions globally.

The CE certification milestone comes shortly after the company reported its global commercial orders for Toumai surpassing 300 units, with aggregate group orders approaching 400 units and first-half orders already exceeding last year's full-year total. The combination of regulatory breakthroughs and accelerating order momentum has effectively alleviated market concerns over competition from Intuitive Surgical's Da Vinci 5 system, which saw Q1 installations double year-over-year to 232 units, and helped absorb residual selling pressure from the company's earlier share placement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)